Search results
Moderna’s flu-Covid combo vaccine elicits ‘strong’ immune response in Phase 1/2 study, company says
CNN via Yahoo News· 8 months agoin a Phase 1/2 clinical trial, Moderna’s combination vaccine appeared to elicit “strong” immune...
Moderna Investors Just Got Some Bullish News
Motley Fool via Yahoo Finance· 2 days agoModerna (NASDAQ: MRNA) jumped into the limelight when it started developing a coronavirus vaccine candidate. And the stock soared as the vaccine raced...
Moderna Crumbles As Cancer Vaccine Data Show A 'Longish And Complex' Road
Investor's Business Daily· 1 year agoModerna stock crumbled Monday after updated results for its Merck-partnered cancer vaccine showed a...
Moderna (MRNA) Posts 2027 Biz View, Down 3% on Flu Jab Setback
Zacks via Yahoo Finance· 1 year agoModerna (MRNA) expects $8-$15 billion in product revenues from the respiratory vaccine by 2027. Its...
Moderna Surges After Flu Shot Beats Out Widely Used Sanofi, GSK Vaccines
Investor's Business Daily· 9 months agoModerna stock popped Wednesday after the company said its experimental flu shot outperformed broadly...
Moderna Just Took a Step Closer to Its Product Launch Goal. Is the Stock a Buy?
Motley Fool via Yahoo Finance· 6 months agoModerna (NASDAQ: MRNA) today is known for its one and only product: the coronavirus vaccine now...
Moderna (MRNA) Up on Upbeat Data From Phase III Study on RSV Jab
Zacks via Yahoo Finance· 1 year agoData from a late-stage study showed that Moderna's (MRNA) RSV vaccine was 83.7% effective at...
Moderna (MRNA) Q4 2023 Earnings Call Transcript
Motley Fool via Yahoo Finance· 3 months agoImage source: The Motley Fool. Moderna (NASDAQ: MRNA) Q4 2023 Earnings Call Feb 22, 2024, 8:00 a.m. ET Contents: Prepared Remarks Questions and Answers...
Moderna Breaks Out For The First Time In A Year After Covid Shot Wallops Sales Views
Investor's Business Daily· 1 month agoModerna stock broke out for the first time in a year on Thursday after beating Wall Street's...
Moderna Stock Soars On 'Transformational' Potential Of Its Merck-Tied Cancer Vaccine
Investor's Business Daily· 6 months agoModerna's Merck-partnered cancer vaccine reduced the risk of relapse or death by 49% in melanoma...
